Dr. Reddy’s divests $33M worth of dermatology brands in India
The generic drugmaker Dr. Reddy’s Laboratories will be divesting several of its dermatology brands in return for about $33 million.
According to a release sent to the National Stock Exchange of India on Thursday, the agreement will see Indian pharma company Eris Lifesciences net the trademark for these brands, which Dr. Reddy’s identified as “non-core brands.” Dr. Reddy’s will be picking up Rs 275 crore, or around $33.2 million. The brands had sales last year of around Rs 60 crore, or $7.2 million, according to the release.
A report from the national news site The Times of India said that a total of nine brands are being let go and that the transaction is expected to be completed at the end of March.
“Today’s announcement is in line with our stated intention of pursuing a strategy that involves growing brands organically combined with acquisitions that are a strategic fit and divestment of non-core brands,” M.V. Ramana, CEO of branded markets at Dr. Reddy’s, said in a statement.
The move does not seem to have had a major impact on its stock price $RDY, which has increased just over 1% since opening on Thursday.
While Dr. Reddy’s may be making some divestments, it has also been looking to boost its overall portfolio. In late February, it acquired Mayne Pharma’s US generics portfolio for at least $90 million in cash, along with a payment of up to $15 million in contingent value rights. Mayne sold around 45 different generics in the US.